Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults (Q80706446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

1 reference

1 reference

1 reference

Nils von Hentig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Brenda Dauer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Annette Haberl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Stefan Klauke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Thomas Lutz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Schlomo Staszewski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Sebastian Harder

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

31 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

935-940

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665183%20AND%20SRC:MED&resulttype=core&format=json

Antiviral hepatitis and antiretroviral drug interactions

2 January 2020

cites work

1 reference

12 December 2020

Clinical practice. Management of newly diagnosed HIV infection

1 reference

12 December 2020

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

1 reference

12 December 2020

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

12 December 2020

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

1 reference

12 December 2020

Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations

1 reference

12 December 2020

Drug-drug interactions and the pharmacotherapy of HIV infection.

1 reference

12 December 2020

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

1 reference

12 December 2020

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

1 reference

12 December 2020

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

1 reference

12 December 2020

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

12 December 2020

A review of low-dose ritonavir in protease inhibitor combination therapy

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring

1 reference

12 December 2020

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

1 reference

12 December 2020

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

1 reference

12 December 2020

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

12 December 2020

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020